Is leukocytosis during the critical phase of dengue a sign of bleeding?

Leukocytosis in Critical Phase Dengue as a Bleeding Indicator

Leukocytosis during the critical phase of dengue is indeed a warning sign of severe complications, particularly massive gastrointestinal bleeding and secondary bacterial infections, rather than a benign recovery marker. 1

Key Clinical Evidence

Leukocytosis as a Pathological Marker

• Fatal dengue cases demonstrate significantly higher proportions of leukocytosis compared to their initial laboratory values, with massive GI bleeding (33.3%) and bacteremia (25%) being the major causes of pre-fatal leukocytosis. 1

• Leukocytosis appears alongside bandemia in fatal cases, suggesting either severe bleeding or concurrent bacterial infection rather than normal immune recovery. 1

• Leukocytosis is specifically identified as a predictor of severe dengue in validated risk scoring systems, with an area under the curve of 0.848-0.904 for predicting severe outcomes. 2

Association with Bleeding

The relationship between leukocytosis and bleeding in critical phase dengue is multifactorial:

• Patients with pre-fatal profound thrombocytopenia (<20,000/µL) had a 33.3% rate of massive GI bleeding, and those with prolonged prothrombin time had a 50% rate of massive GI bleeding. 1

• When leukocytosis occurs with early altered consciousness, it strongly suggests either massive GI bleeding alone, bleeding with uremia, or bleeding with concurrent bacteremia. 1

• The combination of leukocytosis with platelet count ≥100×10⁹ cells/L paradoxically increases severe dengue risk (included in predictive models), suggesting a dysregulated inflammatory response rather than appropriate recovery. 2

Clinical Management Algorithm

When Leukocytosis Appears in Critical Phase:

1. Immediately assess for active bleeding:

   • Examine for gastrointestinal bleeding (hematemesis, melena, hematochezia)
   • Check for hypothermia, which co-occurs with leukocytosis in fatal cases 1
   • Monitor for altered consciousness, present in patients who subsequently develop massive bleeding 1

2. Evaluate for concurrent bacteremia:

   • Empirically initiate antibiotics for patients with leukocytosis and altered consciousness until bacteremia is excluded, as 25% of fatal cases with leukocytosis had bacteremia 1
   • Common organisms include Klebsiella pneumoniae and Enterococcus faecalis 1

3. Intensify coagulation monitoring:

   • Serial platelet counts (massive bleeding risk increases dramatically when <20,000/µL) 1
   • Prothrombin time (50% with prolonged PT develop massive GI bleeding) 1
   • Hematocrit for hemoconcentration versus bleeding-related anemia 1

4. Check for bandemia:

   • Significantly higher bandemia from initial laboratory data distinguishes fatal from non-fatal cases 1
   • Bandemia with leukocytosis strongly suggests bacterial superinfection 1

Critical Pitfalls to Avoid

• Do not interpret leukocytosis as reassuring "immune recovery" during the critical phase—it predicts severe outcomes and mortality. 1, 2

• Do not delay antibiotic therapy in patients with leukocytosis and altered consciousness, as bacteremia contributes to 25% of leukocytosis cases in fatal dengue. 1

• Do not overlook hypothermia, which co-occurs with leukocytosis and represents a warning sign of severe dengue distinct from typical fever patterns. 1

Risk Stratification Context

Age ≥65 years combined with leukocytosis creates particularly high risk (included in validated severe dengue prediction models with sensitivity 70-80% and specificity 85-91%). 2 Patients scoring ≥2 points on validated risk scores have >50% probability of developing severe dengue, warranting intensive monitoring regardless of illness day. 2